MK-1092
Total Payments
$3.1M
Transactions
47
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $98,225 | 1 | 0 |
| 2019 | $5,112 | 4 | 0 |
| 2018 | $1.6M | 29 | 0 |
| 2017 | $1.4M | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 47 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects with Type 1 Diabetes Mellitus, and Subjects with Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $1.7M | 0 |
| A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects and in Subjects with Type 1 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $1.4M | 0 |
Top Doctors Receiving Payments for MK-1092
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chula Vista, CA | $3.1M | 47 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 0
- Transactions 47
About MK-1092
MK-1092 is a drug associated with $3.1M in payments to 0 healthcare providers, recorded across 47 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $98,225 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-1092 is "Unspecified" ($3.1M, 100.0% of total).
MK-1092 is associated with 2 research studies, including "A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects with Type 1 Diabetes Mellitus, and Subjects with Type 2 Diabetes Mellitus" ($1.7M).